<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472705</url>
  </required_header>
  <id_info>
    <org_study_id>003-REP-CER-FR</org_study_id>
    <nct_id>NCT01472705</nct_id>
  </id_info>
  <brief_title>Everolimus- Versus Biolimus-Eluting Stents in All-Comers</brief_title>
  <acronym>EverBio</acronym>
  <official_title>Long-Term Comparison of Everolimus-Eluting and Biolimus-Eluting Stents in All-Comer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study sought to investigate safety and efficacy of biolimus-eluting stents (BES) with
      biodegradable polymer as compared with everolimus-eluting stents (EES) with durable polymer
      through 3 years of follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A group of 814 consecutive patients undergoing percutaneous coronary intervention (PCI) was
      enrolled between 2007 and 2010, of which 527 were treated with EES and 287 with BES
      implantation. Clinical outcome was compared in 200 pairs using propensity score matching. The
      primary endpoint was a composite of death, myocardial infarction (MI) and target vessel
      revascularisation (TVR) at two-year follow-up.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of Death, Myocardial Infarction and Target Vessel Revascularization</measure>
    <time_frame>up to 24 months</time_frame>
    <description>The primary outcome is the above mentioned composite of adverse events in order to measure their cumulative incidence (i.e. the rate of occurrence of such events in the study population over a predefined time periode).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any Revascularization</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">814</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>everolimus-eluting stents (EES)</arm_group_label>
    <description>Second-generation everolimus-eluting stents (EES) have been shown to be superior to the first-generation paclitaxel eluting stents (PES) in terms of safety and efficacy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>biolimus-eluting stents (BES)</arm_group_label>
    <description>Third generation biolimus-eluting stents (BES) have been shown to be superior to the PES and non inferior to first-generation sirolimus eluting stents in terms of safety and efficacy.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients treated at our institution with at least one BES or EES
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  all patients with at least one BES or EES for de novo stenosis

        Exclusion Criteria:

          -  patients with at least one non-study stent

          -  patients with both study stent

          -  patients with life expectancy &lt; 3 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stéphane P Cook, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Fribourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mario Togni, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Fribourg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Markus Oberhänsli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Fribourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cardiology, university Fribourg Medical Center</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <results_reference>
    <citation>Puricel S, Oberhänsli M, Guntern P, Lehmann S, Goy JJ, Arroyo D, Villeneuve H, Baeriswyl G, Stauffer JC, Togni M, Cook S. Long-term comparison of everolimus-eluting and biolimus-eluting stents. EuroIntervention. 2013 Jul;9(3):336-44. doi: 10.4244/EIJV9I3A55.</citation>
    <PMID>23482296</PMID>
  </results_reference>
  <results_reference>
    <citation>Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Trials. 2014 Jan 7;15:9. doi: 10.1186/1745-6215-15-9.</citation>
    <PMID>24398143</PMID>
  </results_reference>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 30, 2011</study_first_submitted>
  <study_first_submitted_qc>November 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Stéphane Cook, Prof</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>drug-eluting coronary stent</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

